ERAL1 and breast cancer: To further validate the ability of site-specific antibodies for phospho-ER-α Ser118 and Ser167 in ER+ and PR+ breast cancer cells, phosphorylation of ER-α Ser118 and Ser167 was analyzed in T47D cells.